^
BIOMARKER:

FOLH1 positive

i
Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
Entrez ID:
Related biomarkers:
1m
Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. (PubMed, Biomedicines)
Based on presented/reviewed data, we consider that scFvD2B, due to its versatility and robustness, seems to: (i) overcome some problems observed in other studied scFvs, very often relatively unstable and prone to form aggregates; (ii) have sufficient tumor-to-background ratios for targeting and imaging PSMA-expressing cancer; (iii) significantly redirect immune killing cells to PSMA-positive tumors when inserted in second-generation CAR-T or NK-92/CAR cells. These data suggest that our product can be considered the right reagent to fill the gap that still exists in PCa diagnosis and treatment.
Review • Journal • IO biomarker
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
2ms
Clinical • New P3 trial
|
BRCA (Breast cancer early onset)
|
BRCA mutation • FOLH1 positive
2ms
Molecular imaging and treatment of PSMA-positive prostate cancer with Tc radiolabeled aptamer-siRNA chimeras. (PubMed, Nucl Med Biol)
Our study proved that [Tc]Tc-Aptamer-siRNA chimeras could be used to diagnose and treat PSMA-positive PCa in vivo.
Journal
|
MDM2 (E3 ubiquitin protein ligase)
|
FOLH1 positive
2ms
Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target? (PubMed, Cancers (Basel))
Radiolabelled PSMA-ligands may, in the future, represent a theranostic approach with only minor side effects for a few individual selected patients with ATC and PDTC who need alternative treatment options in case of progression when established therapies are no longer effective. However, due to the small sample size of our collective, larger studies are needed to allow for a final evaluation on the significance of PSMA-targeted diagnostic and therapy for ATC and PDTC.
Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
5ms
PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state. (PubMed, Prostate)
Our findings revealed the existence of PSMA-positive tumor endothelial cells in human prostate tumors, which enhances tumor angiogenesis in prostate cancer tissues.
Journal
|
FOLH1 (Folate hydrolase 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
FOLH1 expression • FOLH1 positive
5ms
All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation. (PubMed, Nanoscale)
The rather simple structure of docetaxel-loaded Au nanoparticles (NPs) with prostate specific membrane antigen (PSMA) ligand conjugation have been successfully synthesized...In vitro and in vivo investigations confirmed the as-synthesized NPs as an effective nano-radiosensitizer with ideal safety. More importantly, all moieties within the present nanosystem have been approved by FDA for the purpose of PCa treatment, thus making it highly attractive for clinical translation.
Clinical • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
|
docetaxel
6ms
PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome. (PubMed, J Clin Endocrinol Metab)
Our findings show that PSMA expression was present in two-thirds of patients with neck PRD, that it was related to poor prognostic factors and that very high expression was associated with poorer PFS. This preliminary study may offer new perspectives for the management of RAI-refractory DTC.
Clinical • Journal
|
IRS2 (Insulin receptor substrate 2) • FOLH1 (Folate hydrolase 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
CD31 expression • FOLH1 expression • FOLH1 positive
6ms
An Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients. (PubMed, J Nucl Med)
Hence, Zr-PSMA-Df might be of significant benefit to patients in whom the search for weak PSMA-positive lesions is challenging. Radiation exposure should be weighed against the potential benefit of metastasis-directed therapy or salvage radiotherapy, which we initiated in 36% (5/14) of our patients based on their Zr-PSMA-Df PET scans.
Clinical • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
8ms
Clinical • Enrollment open • Combination therapy
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
FOLH1 positive
|
lutetium(177Lu) vipivotide tetraxetan (177 Lu PSMA-617)
10ms
Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. (PubMed, Diagnostics (Basel))
This case illustrates the increased PSMA-avidity in multiple myeloma and highlights PSMA as a potential theragnostic target in multiple myeloma. For clinical routine, lymphatic diseases such as extramedullary myeloma should be considered as differential diagnosis in PSMA-avid renal masses on PET/CT.
Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
11ms
[VIRTUAL] Amanitin-based ADCs targeting PSMA as novel therapeutic modality for prostate cancer therapy (AACR 2021)
Targeted cytotoxic drug delivery to PSMA positive cell lines was achieved by using anti-PSMA ATACs optimized for the use in solid tumors. The mode of action of the payload amanitin led to an efficient anti-tumor potential in vitro and in vivo with good tolerability in non-human primates. Using ATACs in the therapy of PSMA positive prostate cancer is a promising approach, especially by using a cytotoxic agent whose mode of action differs from other commonly used toxins.
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 positive
|
PSMA-ATAC
11ms
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (clinicaltrials.gov)
P3, N=1126, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2028 --> Nov 2025 | Trial primary completion date: Jun 2027 --> Jul 2024
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
FOLH1 positive
|
lutetium(177Lu) vipivotide tetraxetan (177 Lu PSMA-617)
12ms
VISION: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
P3, N=750, Active, not recruiting, Endocyte | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Jan 2021
Clinical • Trial completion date • Trial primary completion date
|
ALB (Albumin)
|
FOLH1 positive
|
lutetium(177Lu) vipivotide tetraxetan (177 Lu PSMA-617)
1year
Clinical • New P3 trial • Combination therapy
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
FOLH1 positive
|
lutetium(177Lu) vipivotide tetraxetan (177 Lu PSMA-617)
1year
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. (PubMed, Prostate)
Collectively, the data provide evidence in favor of the hypothesis that patients with high PSMA uptake and high administered radionuclide dose correlate with a higher chance of response.
Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 positive
|
lutetium(177Lu) vipivotide tetraxetan (177 Lu PSMA-617)
1year
[F]-JK-PSMA-7 and [F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice. (PubMed, Eur J Nucl Med Mol Imaging)
Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.
Preclinical • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 positive
|
docetaxel
1year
Molecular imaging of prostate cancer targeting CD46 using immunoPET. (PubMed, Clin Cancer Res)
[89Zr]DFO-YS5 is an excellent PET imaging agent across a panel of prostate cancer models, including in both adenocarcinoma and neuroendocrine prostate cancer, both cell line- and patient-derived xenografts, and both PSMA positive and negative tumors. It demonstrates potential for clinical translation as an imaging agent, theranostic platform, and companion biomarker in prostate cancer.
Journal
|
AR (Androgen receptor)
|
FOLH1 positive
1year
Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. (PubMed, J Nucl Med)
Higher PSA-levels after RARP and positive pathological lymph node status were significantly associated with metastases outside the prostatic fossa. In conclusion, in patients with BCP, PSMA PET/CT imaging is warranted to guide (salvage) treatment strategies.
Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 positive
1year
[Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. (PubMed, EJNMMI Res)
Post-ADT scans detected, especially in patients with a residual PSA < 1 ng/ml, fewer PSMA-positive lesions with overall lower PSMA expression, regardless of primary tumor site or metastatic sites. None of the PET parameters has proven to be superior, as they all correlated modestly with the PSA value at T2. Thus, the simply acquirable miPSMA score seems to be the most suitable for evaluating the effect of ADT on PSMA expression.
Retrospective data • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 positive
over1year
Dynamic Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study. (PubMed, J Nucl Med)
This pilot study demonstrated DPSMA uptake and kinetics in localized renal masses. Increased Ga-PSMA-11 tracer uptake and intra-tumoral retention correlate with PSMA expression in malignant renal tumors compared with benign renal masses, supporting further assessment of DPSMA as a potential tool for evaluating localized renal masses.
Clinical • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 positive